Article History
Received: 1 May 2020
Revised: 23 June 2020
Accepted: 29 June 2020
First Online: 21 July 2020
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Not applicable.
: D.K.—travel grants: AstraZeneca. A.S.—stock ownership or equity: none. Employee, office, directorship: none. Leadership in: none. Consultancy/advisory arrangements: Merck (compensated), Bristol-Myers Squibb (compensated), Novartis (compensated), Oncorus (compensated), Janssen (compensated). Speaker’s Bureau for: none. Grant/Research support from (Clinical Trials for Institution): Novartis, Bristol-Myers Squibb, Symphogen AstraZeneca/Medimmune, Merck, Bayer, Surface Oncology, Northern Biologics, Janssen Oncology/Johnson & Johnson, Roche, Regeneron, Alkermes, Array Biopharma, GSK. Travel grants: none. Intellectual property rights: none. L.L.S.—stock ownership or equity: Agios (spouse). Employee, office, directorship: none. Leadership in: Treadwell therapeutics (spouse=co-founder). Consultancy/advisory arrangements: Merck (compensated), Pfizer (compensated), Celgene (compensated), AstraZeneca/Medimmune (compensated), Morphosys (compensated), Roche (compensated), GeneSeeq (compensated), Loxo (compensated), Oncorus (compensated), Symphogen (compensated), Seattle Genetics (compensated), GSK (compensated), Voronoi (compensated), Treadwell Therapeutics (compensated), Arvinas (compensated), Tessa (compensated), Navire (compensated), Relay (compensated), Rubius (compensated). Speaker’s Bureau for: none. Grant/Research support (Clinical Trials for Institution): Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche/Genentech, Karyopharm, AstraZeneca/Medimmune, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Symphogen, Intensity Therapeutics, Mirati, Shattucks, Avid. Travel grants: none. Intellectual property rights: none.
: L.L.S. holds the BMO Chair in Precision Cancer Genomics.